碳酸司维拉姆治疗维持性血液透析患者高磷血症疗效观察  

Efficacy of sevelamer carbonate on hyperphosphatemia patients undergoing maintenance hemodialysis

作　　者：谭鹤长[1] 宋雪霞[1] 刘春晓[1] 

机构地区：[1]广西医科大学第四附属医院肾内科,广西柳州545005

出　　处：《新疆医科大学学报》2013年第7期974-975,978,共3页Journal of Xinjiang Medical University

基　　金：广西自治区自然基金项目(2011JJA40452)

摘　　要：目的评价碳酸司维拉姆治疗终末期肾病维持性血液透析(MHD)患者高磷血症的疗效。方法分析21例给予碳酸司维拉姆治疗的MHD患者透析前血磷、血钙、钙磷乘积和全段甲状旁腺激素(iPTH)水平,观察时间为16w。治疗期间每2周检测血清钙磷水平并根据结果调整治疗剂量。结果碳酸司维拉姆治疗2w后,患者血磷和血清钙磷乘积水平即开始明显下降。16w疗程结束时,与治疗前比较,患者血磷[(1.64±0.59)、(2.97±0.81)mmol/L,P<0.05]、钙磷乘积[(52.3±13.4)、(79.6±12.8)mg2/dL2,P<0.01]显著下降,而血浆iPTH水平和血钙水平无显著变化。结论碳酸司维拉姆能有效降低MHD患者血磷和钙磷乘积水平。Objective To evaluate the efficacy of sevelamer carbonate in treating maintenance hemodialysis （MHD） patients with hyperphosphatemia. Methods 21 MHD patients were treated with sevelamer car-bonate for 16 weeks. The serum level of calcium, phosphorus, calcium-phosphorus product and intact par-athyroid hormone （iPTH） were detected every 2 weeks during treatment and the dose was adjusted accord-ing to the testing data. Results After two weeks of treatment with sevelamer carbonate, serum phosphor-us and serum calcium-phosphorus product levels decreased. By the end of treatment, compared with before treatment, the level of serum phosphorus [-（1.64±0.59） vs （2.97±0.81） mmol/L, P %0.05] and serum calcium-phosphorus product [（52.3±13.4） vs （79.6±12.8） mg^2/dL2, P 〈0.01t] were significantly de-creased, while the serum level of calcium and serum iPTH had no significant change. Conclusion Sevel-amer carbonate can effectively reduce serum level of phosphorus and calcium-phosphorus product in MHD patients.

关 键 词：终末期肾病 血液透析 碳酸司维拉姆 高磷血症 

分 类 号：R459.5[医药卫生—治疗学]